PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky
Igår, 22:28
PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky
PR Newswire
NEW YORK, March 18, 2026
Insulet CEO Called Omnipod 5 "Reliable" and a "Favorite Pump" on February 18 -- Two Weeks Later, the Company Disclosed a Voluntary Recall Covering Thousands of Defective Pods
NEW YORK , March 18, 2026 /PRNewswire/ -- On February 18, 2026, Insulet Corp. (NASDAQ: PODD) CEO Ashley McEvoy told investors on the Q4 2025 earnings call that "our results in the fourth quarter are a testament to the reliability, consistency and broad appeal of Omnipod." On March 12, 2026, the Company filed an 8-K disclosing a voluntary medical-device correction for Omnipod 5 pods due to an insulin-leakage defect linked to eighteen serious adverse events -- and PODD shares fell 6.9%. Shareholders who lost money on PODD are encouraged to submit their information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025. CFO Flavia Pease added that U.S. revenue growth was "above the high end of our guidance range, driven by continued demand for Omnipod 5 across type 1 and type 2 customers." At no point during the call did any executive reference a product-quality issue, a pending regulatory action, or an anticipated recall.
Only a few weeks later, the March 12 filing revealed a defect affecting Omnipod 5 Pods. The filing identified insulin leakage capable of causing diabetic ketoacidosis -- a serious medical emergency. The Company's February 18 statements about Omnipod reliability, patient confidence, and demand-driven growth had not referenced any of these issues.
If you purchased Insulet Corp. shares and suffered a loss, click here to discuss your legal rights . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE Levi & Korsinsky
Ämnen i artikeln
PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky
Igår, 22:28
PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky
PR Newswire
NEW YORK, March 18, 2026
Insulet CEO Called Omnipod 5 "Reliable" and a "Favorite Pump" on February 18 -- Two Weeks Later, the Company Disclosed a Voluntary Recall Covering Thousands of Defective Pods
NEW YORK , March 18, 2026 /PRNewswire/ -- On February 18, 2026, Insulet Corp. (NASDAQ: PODD) CEO Ashley McEvoy told investors on the Q4 2025 earnings call that "our results in the fourth quarter are a testament to the reliability, consistency and broad appeal of Omnipod." On March 12, 2026, the Company filed an 8-K disclosing a voluntary medical-device correction for Omnipod 5 pods due to an insulin-leakage defect linked to eighteen serious adverse events -- and PODD shares fell 6.9%. Shareholders who lost money on PODD are encouraged to submit their information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025. CFO Flavia Pease added that U.S. revenue growth was "above the high end of our guidance range, driven by continued demand for Omnipod 5 across type 1 and type 2 customers." At no point during the call did any executive reference a product-quality issue, a pending regulatory action, or an anticipated recall.
Only a few weeks later, the March 12 filing revealed a defect affecting Omnipod 5 Pods. The filing identified insulin leakage capable of causing diabetic ketoacidosis -- a serious medical emergency. The Company's February 18 statements about Omnipod reliability, patient confidence, and demand-driven growth had not referenced any of these issues.
If you purchased Insulet Corp. shares and suffered a loss, click here to discuss your legal rights . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE Levi & Korsinsky
Ämnen i artikeln
Analys
Bostadsmarknaden
Analys
Bostadsmarknaden
Marknadsöversikt
1 DAG %
Senast
1 mån
